Abstract
An objective was to explore the photodynamic activity of two cationic photosensitizers (PS) (benzo[a]phenothiazinium chloride and benzo[a]phenoselenazinium chloride) against Mycobacterium bovis BCG both in vitro and in a murine model of BCG-granuloma. The hypothesis being tested in this study was that cationic molecules could best interact with the negatively charged membrane of BCG as a model for mycobacterial infection. Cells in culture were incubated with various concentrations of PS and subsequently illuminated using a 635 nm diode laser. Dark- and light-induced killing profiles were generated as a function of fluence and dye concentration. In vivo, local injection of the PS into subcutaneous Mycobacterium-induced granuloma sites in murine model was followed by red light illumination of the same area. A special microscope was fabricated for real-time in vivo fluorescent microscopy to monitor EtNBS delivery to subcutaneous murine granulomata. Both PS demonstrated good in vitro antimycobacterial photodynamic activity with varying degrees of toxicity under dark conditions. Real time in vivo monitoring of benzophenothiazine chloride in the mouse model indicated that this fluorescent photosensitizer was delivered rapidly to the subcutaneous granuloma site. In vivo, photosensitizer specific dark- and photo-toxicities depended on the structure, concentration of the photosensitizer and the light dose utilized. Cationic phenothiazine photosensitizers are promising candidates for use in anti-mycobacterial PDT for localized diseases such as cutaneous and pulmonary granulomata.
Similar content being viewed by others
References
M. R. Hamblin, and T. Hasan, Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem. Photobiol. Sci., 2004, 3, 436–450.
G. P. Tegos, and M. R. Hamblin, Phenothiazinium antimicrobial photosensitizers are substrates of bacterial multidrug resistance pumps, Antimicrob. Agents Chemother., 2006, 50, 196–203.
S. B. Brown, Clinical studies using antimicrobial PDT, in 11th World Congress of the International Photodynamic Association, Shanghai, China, 2007, p. 51.
K. O’Riordan, O. E. Akilov, and T. Hasan, The potential for photodynamic therapy in the treatment of localized infections, Photodiagn. Photodyn. Ther., 2005, 2, 247–262.
T. Hasan, B. Ortel, A. C. E. Moor and and B. W. Pogue, Chapter 40. Photodynamic therapy of cancer, in Cancer Medicine, ed. H. Frei, BC Dekker, Inc., New York, NY, USA, 2003, pp. 605–622.
A. P. Castano, T. N. Demidova, and M. R. Hamblin, Mechanisms in photodynamic therapy: Part One - Photosensitizers, photochemistry and cellular localization, Photodiagn. Photodyn. Ther., 2004, 1, 279–293.
G. Jori, and S. B. Brown, Photosensitized inactivation of microorganisms, Photochem. Photobiol. Sci., 2004, 3, 403–405.
T. Maisch, R. M. Szeimies, G. Jori, and C. Abels, Antibacterial photodynamic therapy in dermatology, Photochem. Photobiol. Sci., 2004, 3, 907–917.
S. B. Brown, Antimicrobial PDT: we have heard the theory, what about the practice? in The 11th Congress of the European Society for Photobiology, ed. J. Piette, Aix-les-Bains, France, 2005, p. 100.
K. O’Riordan, D. S. Sharlin, J. Gross, S. Chang, D. Errabelli, O. E. Akilov, S. Kosaka, G. J. Nau, and T. Hasan, Photoinactivation of Mycobacteria in vitro and in a new murine model of localized Mycobacterium bovis BCG-induced granulomatous infection, Antimicrob. Agents Chemother., 2006, 50, 1828–1834.
M. S. Glickman, W. R. Jacobs, Jr., Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline, Cell, 2001, 104, 477–485.
M. D. Iseman, MDR-TB and the developing world–a problem no longer to be ignored: the WHO announces ‘DOTS Plus’ strategy, Int. J. Tuberc. Lung Dis., 1998, 2, 867.
E. Nathanson, R. Gupta, P. Huamani, V. Leimane, A. D. Pasechnikov, T. E. Tupasi, K. Vink, E. Jaramillo, and M. A. Espinal, Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative, Int. J. Tuberc. Lung Dis., 2004, 8, 1382–1384.
P. Godfrey-Faussett, and H. Ayles, Can we control tuberculosis in high H prevalence settings? Tuberculosis, 2003, 83, 68–76.
P. Ravn, M. E. Munk, A. B. Andersen, B. Lundgren, L. N. Nielsen, T. Lillebaek, I. J. Soerensen, P. Andersen, and K. Weldingh, Reactivation of tuberculosis during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test, Scand. J. Infect. Dis., 2004, 36, 499–501.
M. I. Perelman, and V. P. Strelzov, Surgery for pulmonary tuberculosis, World J. Surg., 1997, 21, 457–467.
C. E. Millson, M. Wilson, A. J. MacRobert, and S. G. Bown, Ex vivo treatment of gastric Helicobacter infection by photodynamic therapy, J. Photochem. Photobiol., B, 1996, 32, 59–65.
M. Wainwright, The development of phenothiazinium photosensitisers, Photodiagn. Photodyn. Ther., 2005, 2, 263–272.
L. Cincotta, D. Szeto, E. Lampros, T. Hasan, and A. H. Cincotta, Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas, Photochem. Photobiol., 1996, 63, 229–237.
D. A. Phoenix, Z. Sayed, S. Hussain, F. Harris, and M. Wainwright, The phototoxicity of phenothiazinium derivatives against Escherichia coli and Staphylococcus aureus, FEMS Immunol. Med. Microbiol., 2003, 39, 17–22.
M. N. Usacheva, M. C. Teichert, and M. A. Biel, The role of the methylene blue and toluidine blue monomers and dimers in the photoinactivation of bacteria, J. Photochem. Photobiol., B, 2003, 71, 87–98.
M. Wainwright, D. A. Phoenix, S. L. Laycock, D. R. Wareing, and P. A. Wright, Photobactericidal activity of phenothiazinium dyes against methicillin-resistant strains of Staphylococcus aureus, FEMS Microbiol. Lett., 1998, 160, 177–181.
M. Wainwright, D. A. Phoenix, J. Marland, D. R. Wareing, and F. J. Bolton, A study of photobactericidal activity in the phenothiazinium series, FEMS Immunol. Med. Microbiol., 1997, 19, 75–80.
J. W. Foley, X. Song, T. N. Demidova, F. Jalil, and M. R. Hamblin, Synthesis and Properties of Benzo[a]phenoxazinium Chalcogen Analogues as Novel Broad-Spectrum Antimicrobial Photosensitizers, J. Med. Chem., 2006, 49, 7252.
O. E. Akilov, S. Kosaka, K. O’Riordan, X. Song, M. Sherwood, T. J. Flotte, J. W. Foley, and T. Hasan, The Role of Photosensitizer Molecular Charge and Structure on the Efficacy of Photodynamic Therapy against Leishmania Parasites, Chem. Biol., 2006, 13, 839–847.
L. Amaral, J. E. Kristiansen, M. Viveiros, and J. Atouguia, Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy, J. Antimicrob. Chemother., 2001, 47, 505–511.
D. Ordway, M. Viveiros, C. Leandro, R. Bettencourt, J. Almeida, M. Martins, J. E. Kristiansen, J. Molnar, and L. Amaral, Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis, Antimicrob. Agents Chemother., 2003, 47, 917–922.
Y. Zhang, The magic bullets and tuberculosis drug targets, Annu. Rev. Pharmacol. Toxicol., 2005, 45, 529–564.
F. A. Salih, N. K. Kaushik, P. Sharma, G. V. Choudary, P. S. Murthy, and T. A. Venkitasubramanian, Calmodulin-like activity in mycobacteria, Indian J. Biochem. Biophys., 1991, 28, 491–495.
J. T. Groves, S. M. Lindenauer, B. J. Haywood, J. A. Knol, and J. S. Schultz, Synthesis of seleno-toluidine blue, J. Med. Chem., 1974, 17, 902–904.
M. J. Hickey, T. M. Arain, R. M. Shawar, D. J. Humble, M. H. Langhorne, J. N. Morgenroth, and C. K. Stover, Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice, Antimicrob. Agents Chemother., 1996, 40, 400–407.
K. I. Moller, B. Kongshoj, P. A. Philipsen, V. O. Thomsen, and H. C. Wulf, How Finsen’s light cured lupus vulgaris, Photodermatol. Photoimmunol. Photomed., 2005, 21, 118–124.
S. G. Bown, and A. Z. Rogowska, New photosensitizers for photodynamic therapy in gastroenterology, Can. J. Gastroenterol., 1999, 13, 389–392.
S. Kosaka, O. E. Akilov, K. O’Riordan, and T. Hasan, A mechanistic study of d-aminolevulinic acid–based photodynamic therapy for cutaneous leishmaniasis, J. Invest. Dermatol., 2007, 127, 1546–1549.
O. E. Akilov, S. Kosaka, K. O’Riordan, and T. Hasan, Parasiticidal effect of delta-aminolevulinic acid–based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells, Exp. Dermatol., 2007, 16, 651–660.
L. Cincotta, J. W. Foley, and A. H. Cincotta, Phototoxicity, redox behavior, and pharmacokinetics of benzophenoxazine analogues in EMT-6 murine sarcoma cells, Cancer Res., 1993, 53, 2571–2580.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
O’Riordan, K., Akilov, O.E., Chang, S.K. et al. Real-time fluorescence monitoring of phenothiazinium photosensitizers and their anti-mycobacterial photodynamic activity against Mycobacterium bovis BCG in in vitro and in vivo models of localized infection. Photochem Photobiol Sci 6, 1117–1123 (2007). https://doi.org/10.1039/b707962a
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1039/b707962a